Insilico Medicine and ChemDiv Form a Strategic Drug Discovery Service Alliance

Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration combines the most advanced artificial intelligence (AI) techniques with a premium integrated drug discovery shared risk platform. The combination of complementary capabilities introduces a new value for companies working in the field, giving them a powerful tool for quick, cost-effective therapeutic product development.

Read More: Reputation In The Online World: How Brands Can Cut Through The Endless Choices Of The Customer Journey

“We’re pleased to partner with ChemDiv, the leading discovery contract research organization, which built a massive repository of small molecules,” said Alex Zhavoronkov, PhD., CEO of Insilico Medicine. “ChemDiv has had a number of highly successful collaborations with pharmaceutical companies in multiple therapeutic areas, moving their discoveries from the unique chemistry idea into the clinic. Together we will improve the novelty, quality and efficiency of preclinical drug discovery and bring our technology and experience to other biotech and pharma partners.”

Read More: Talkwalker Launches AI-Powered Solution To Better Analyze Customer Conversation Data

Sergey Bugrov, Executive Director of ChemDiv commented, “With Insilico Medicine’s AI technology previously intractable targets could become viable therapeutic opportunities and the time for preclinical drug discovery could dramatically shorten. Our joint goal is to generate new leads against identified and predicted novel targets. It allows us to continuously deliver great service to our partners and help them develop effective treatments for unmet medical needs.”

Read More: Drone Racing League Launches DRL RacerAI, the First-Ever Autonomous Racing Drone